First human test for new prostate cancer imaging agent
NCT ID NCT06520449
Summary
This study is testing a new imaging agent called 68Ga-NTA-476 for PET scans in men with prostate cancer. It's the first time this agent is being used in people. The main goals are to see where the agent travels in the body after injection, how it compares to the current standard imaging agent, and to check for any side effects. Ten participants will receive both the new and standard scans to make this comparison.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Melbourne Theranostic Innovation Centre
Melbourne, Victoria, 3051, Australia
Conditions
Explore the condition pages connected to this study.